Polygenic risk score for drug-induced long QT syndrome: independent validation in a real-world patient cohort
Pharmacogenetics and Genomics · 2025-01 · 35 (1) · 45-56
DOI: 10.1097/fpc.0000000000000548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacogenetics and Genomics, online erschienen am 08.10.2024. Verfasst von Ana I Lopez-Medina und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Long QT Syndrome, Multifactorial Inheritance. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIBIB NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Objective
Drug-induced long QT syndrome (diLQTS) is an adverse reaction from over 150 FDA-approved medications, posing the risk of triggering torsades de pointes and sudden death. While common genetic variants may modestly impact QT interval individually, their collective effect can significantly amplify risk of diLQTS. Consequently, this study aimed to validate a polygenic risk score (PRS) for diLQTS previously proposed by Strauss et al .
Methods
A retrospective cohort study was conducted utilizing patients from the Michigan Genomics Initiative prescribed 27 high-risk QT-prolonging drugs and an ECG during the prescription. The primary outcome was marked prolongation of the QTc interval (either >60 ms change from baseline or >500 ms absolute value) during treatment with a high-risk QT-prolonging drug.
Results
The primary outcome occurred in 12.0% of n = 6070 self-reported White, 12.4% of 558 African American, and 8.2% of 110 Asian patients. The PRS significantly associated with diLQTS in White patients [adjusted odds ratio = 1.44 (95% CI: 1.09–1.89); P = 0.009]. However the study lacked sufficient statistical power to confirm the PRS as a risk factor in African Americans [adjusted odds ratio = 2.18 (95% CI: 0.98–5.49); P = 0.073] and Asians [adjusted odds ratio = 3.21 (95% CI: 0.69–16.87); P = 0.139] due to smaller sample sizes in these groups.
Conclusion
The previously published PRS for diLQTS was validated in a large, real-world cohort, demonstrating its potential as a tool for identifying high-risk patients. Incorporating this PRS into routine clinical practice could enable proactive measures to prevent life-threatening diLQTS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan.
- Center for Inherited Cardiovascular Diseases, WellSpan Health, Lancaster, Pennsylvania.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Cardiology, Barts Heart Centre.
- William Harvey Research Institute, Queen Mary University of London, London, UK.
- Center for Arrhythmia Research, Departments of Internal Medicine - Cardiology, Biomedical Engineering, and Applied Physics, University of Michigan, Ann Arbor, Michigan, USA.
Förderung
- NHLBI NIH HHS
- NIBIB NIH HHS
- NCATS NIH HHS
- Department of Defense
Zitieren
APA
Lopez-Medina, A. I., Campos-Staffico, A. M., Chahal, C. A. A., Jacoby, J. P., Volkers, I., Berenfeld, O., & Luzum, J. A. (2025). Polygenic risk score for drug-induced long QT syndrome: independent validation in a real-world patient cohort. Pharmacogenetics and Genomics, 35(1), 45-56. https://doi.org/10.1097/fpc.0000000000000548
Vancouver
Lopez-Medina AI, Campos-Staffico AM, Chahal CAA, Jacoby JP, Volkers I, Berenfeld O, et al. Polygenic risk score for drug-induced long QT syndrome: independent validation in a real-world patient cohort. Pharmacogenetics and Genomics. 2025;35(1):45-56. doi:10.1097/fpc.0000000000000548
BibTeX
@article{LopezMedina2025,
author = {Lopez-Medina, Ana I and Campos-Staffico, Alessandra M and Chahal, Choudhary Anwar A and Jacoby, Juliet P and Volkers, Isabella and Berenfeld, Omer and Luzum, Jasmine A},
title = {Polygenic risk score for drug-induced long QT syndrome: independent validation in a real-world patient cohort},
journal = {Pharmacogenetics and Genomics},
year = {2025},
volume = {35},
number = {1},
pages = {45--56},
doi = {10.1097/fpc.0000000000000548}
}
EUVIMED